• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Novel Urea-Containing Compounds as Orexin Receptor Agonists for Treating Sleep Disorders, Namely, Narcolepsy, Hypersomnia, and Sleep Apnea Syndrome.新型含尿素化合物作为食欲素受体激动剂用于治疗睡眠障碍，即发作性睡病、发作性嗜睡症和睡眠呼吸暂停综合征。
ACS Med Chem Lett. 2025 Feb 18;16(3):375-376. doi: 10.1021/acsmedchemlett.5c00067. eCollection 2025 Mar 13.
2
Novel Compounds as Orexin Receptor Agonists for Treating Sleep Disorders, Namely, Narcolepsy and Hypersomnia.用于治疗睡眠障碍（即发作性睡病和发作性嗜睡症）的新型食欲素受体激动剂化合物。
ACS Med Chem Lett. 2024 Jul 3;15(8):1178-1179. doi: 10.1021/acsmedchemlett.4c00285. eCollection 2024 Aug 8.
3
Sulfonamide Compounds as Orexin Receptor Agonists for Treating Sleep Disorders, Namely, Narcolepsy and Hypersomnia.作为用于治疗睡眠障碍（即发作性睡病和发作性嗜睡症）的食欲素受体激动剂的磺胺类化合物。
ACS Med Chem Lett. 2023 Dec 29;15(1):17-18. doi: 10.1021/acsmedchemlett.3c00546. eCollection 2024 Jan 11.
4
Novel Pyrrolidinone Urea Compounds as FPR2 Agonists for Treating Atherosclerosis and Heart Failure.新型吡咯烷酮脲化合物作为治疗动脉粥样硬化和心力衰竭的FPR2激动剂
ACS Med Chem Lett. 2024 Nov 14;15(12):2093-2094. doi: 10.1021/acsmedchemlett.4c00536. eCollection 2024 Dec 12.
5
Novel Tryptamine Compounds as 5-HT2A Agonists for Treating Mood Disorders such as Depressive Disorders and Bipolar Disorders.新型色胺化合物作为5-HT2A激动剂用于治疗情绪障碍，如抑郁症和双相情感障碍。
ACS Med Chem Lett. 2025 Feb 13;16(3):373-374. doi: 10.1021/acsmedchemlett.5c00047. eCollection 2025 Mar 13.
6
Novel Ergoline Compounds as 5-HT2A Agonists for Treating Mood Disorders Such as Depressive Disorders and Bipolar Disorders.新型麦角灵化合物作为5-HT2A激动剂用于治疗情绪障碍，如抑郁症和双相情感障碍。
ACS Med Chem Lett. 2024 Dec 20;16(1):32-33. doi: 10.1021/acsmedchemlett.4c00593. eCollection 2025 Jan 9.
7
Novel Carbocyclic Phenylpyrrolidinone Urea Compounds as FPR2 Agonists for Treating Atherosclerosis and Heart Failure.新型碳环苯基吡咯烷酮脲化合物作为治疗动脉粥样硬化和心力衰竭的FPR2激动剂
ACS Med Chem Lett. 2025 Jan 10;16(2):186-187. doi: 10.1021/acsmedchemlett.4c00614. eCollection 2025 Feb 13.
8
Novel Pyrrolidinone Urea as FPR2 Agonists for Treating Atherosclerosis and Heart Failure.新型吡咯烷酮脲作为治疗动脉粥样硬化和心力衰竭的FPR2激动剂
ACS Med Chem Lett. 2025 Apr 21;16(5):756-757. doi: 10.1021/acsmedchemlett.5c00196. eCollection 2025 May 8.
9
Practice parameters for the surgical modifications of the upper airway for obstructive sleep apnea in adults.成人阻塞性睡眠呼吸暂停上气道手术矫正的实践参数。
Sleep. 2010 Oct;33(10):1408-13. doi: 10.1093/sleep/33.10.1408.
10
Novel Compounds as 5-HT2A Agonists for Treating Mental Illness or CNS Disorders.作为用于治疗精神疾病或中枢神经系统疾病的5-HT2A激动剂的新型化合物。
ACS Med Chem Lett. 2025 Feb 11;16(3):377-378. doi: 10.1021/acsmedchemlett.5c00066. eCollection 2025 Mar 13.

本文引用的文献

1
The mechanism of different orexin/hypocretin neuronal projections in wakefulness and sleep.不同食欲素/下丘脑泌素神经元投射在清醒和睡眠中的机制。
Brain Res. 2025 Mar 1;1850:149408. doi: 10.1016/j.brainres.2024.149408. Epub 2024 Dec 19.
2
Novel Compounds as Orexin Receptor Agonists for Treating Sleep Disorders, Namely, Narcolepsy and Hypersomnia.用于治疗睡眠障碍（即发作性睡病和发作性嗜睡症）的新型食欲素受体激动剂化合物。
ACS Med Chem Lett. 2024 Jul 3;15(8):1178-1179. doi: 10.1021/acsmedchemlett.4c00285. eCollection 2024 Aug 8.
3
Orexin increases the neuronal excitability of several brain areas associated with maintaining of arousal.食欲素增加了与维持觉醒相关的几个脑区的神经元兴奋性。
J Neurochem. 2024 Sep;168(9):2379-2390. doi: 10.1111/jnc.16195. Epub 2024 Aug 2.
4
Narcolepsy and rapid eye movement sleep.发作性睡病与快速眼动睡眠
J Sleep Res. 2025 Apr;34(2):e14277. doi: 10.1111/jsr.14277. Epub 2024 Jul 2.
5
Clinical usefulness of dual orexin receptor antagonism beyond insomnia: Neurological and psychiatric comorbidities.双重食欲素受体拮抗剂在失眠症之外的临床应用：神经和精神共病。
Neuropharmacology. 2024 Mar 1;245:109815. doi: 10.1016/j.neuropharm.2023.109815. Epub 2023 Dec 17.

新型含尿素化合物作为食欲素受体激动剂用于治疗睡眠障碍，即发作性睡病、发作性嗜睡症和睡眠呼吸暂停综合征。

Novel Urea-Containing Compounds as Orexin Receptor Agonists for Treating Sleep Disorders, Namely, Narcolepsy, Hypersomnia, and Sleep Apnea Syndrome.

作者信息

Sabnis Ram W

机构信息

Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.

出版信息

ACS Med Chem Lett. 2025 Feb 18;16(3):375-376. doi: 10.1021/acsmedchemlett.5c00067. eCollection 2025 Mar 13.

DOI:10.1021/acsmedchemlett.5c00067
PMID:40104798
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11912266/
Abstract

Provided herein are novel urea-containing compounds as orexin receptor agonists, pharmaceutical compositions, use of such compounds in treating sleep disorders, namely, narcolepsy, hypersomnia, and sleep apnea syndrome as well as processes for preparing such compounds.

摘要

本文提供了作为食欲素受体激动剂的新型含尿素化合物、药物组合物、此类化合物在治疗睡眠障碍即发作性睡病、发作性嗜睡症和睡眠呼吸暂停综合征中的用途以及制备此类化合物的方法。